FirstLine – Newsemia

Anti-TNF therapy appears effective after first-line Entyvio in IBD

NewsemiaDecember 9, 2019

by NewsemiaDecember 9, 201900

SAN ANTONIO — In patients with inflammatory bowel disease, first-line vedolizumab treatment did not appear to compromise the effectiveness of successive anti-TNF treatment in real-world...

Gastroenterology

First-Line Combo Improves Survival in Advanced HCC

NewsemiaNovember 24, 2019

by NewsemiaNovember 24, 201900

<![CDATA[]]>(MedPage Today) — For the first time in more than a decade, patients with hepatocellular carcinoma (HCC) lived significantly longer with a new upfront therapy...

Latest News

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

NewsemiaNovember 24, 2019

by NewsemiaNovember 24, 201900

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...

Pharma / Biotech

When First-Line HCC Rx Fails, What Comes Next?

NewsemiaOctober 21, 2019

by NewsemiaOctober 21, 201900

Although the emergence of sorafenib in the front-line setting for hepatocellular carcinoma (HCC) has changed practice, many clinicians continue to debate the best second-line agent...

Pharma / Biotech

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

NewsemiaOctober 18, 2019

by NewsemiaOctober 18, 201900

Related Articles A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. J...

Latest News

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

NewsemiaSeptember 28, 2019

by NewsemiaSeptember 28, 201900

KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–LYNPARZA PAOLA-1 Trial Significantly Increased PFS as 1st-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer Source link...

Latest News

Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients

NewsemiaSeptember 8, 2019

by NewsemiaSeptember 8, 201900

Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile in special populations with advanced non-small cell...

Pediatrics

Non-Cystic Fibrosis Bronchiectasis: Which First-Line Antibiotic Is BEST for Kids?

NewsemiaSeptember 5, 2019

by NewsemiaSeptember 5, 201900

(MedPage Today) — Amoxicillin-clavulanate a good option, but questions remain about use in all kids Source link...

Gastroenterology

Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin

NewsemiaJuly 25, 2019

by NewsemiaJuly 25, 201900

Eradicating Helicobacter pylori infection is clinically challenging, notably in cases with penicillin allergy. Cephalosporin could be used in lieu of amoxicillin to eradicate Helicobacter pylori....

Gastroenterology

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

NewsemiaJuly 9, 2019

by NewsemiaJuly 9, 201900

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial) Source link...

Latest News

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

NewsemiaMay 28, 2019

by NewsemiaMay 28, 201900

STRASBOURG, France–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/TG4010?src=hash" target="_blank"gt;#TG4010lt;/agt;–Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces...

Latest News

Simplifying switch to second line ART: Predicted effect of defining failure of first-line efavirenz-based regimens in sub-Saharan Africa by a single viral load > 1000 copies/ml

NewsemiaMay 15, 2019

by NewsemiaMay 15, 201900

Shroufi, A; Van Cutsem, G; Cambiano, V; Bansi-Matharu, L; Duncan, K; Murphy, RA; Maman, D; Shroufi, A; Van Cutsem, G; Cambiano, V; Bansi-Matharu, L; Duncan,...

Latest News

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen

NewsemiaMay 13, 2019

by NewsemiaMay 13, 201900

Armenia, D; Di Carlo, D; Cozzi-Lepri, A; Calcagno, A; Borghi, V; Gori, C; Bertoli, A; … ICONA Foundation Study Group, ; + view all Armenia,...

Pharma / Biotech

FDA Approves Ivosidenib as First-Line Therapy for AML

NewsemiaMay 4, 2019

by NewsemiaMay 4, 201900

The agency reviewed the application for ivosidenib using its Real-Time Oncology Review pilot program. Source link...

Pharma / Biotech

Keytruda Gains 2 New First-Line Indications: NSCLC and RCC

NewsemiaApril 25, 2019

by NewsemiaApril 25, 201900

The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with stage III/IV non-small cell lung cancer who are not candidates for surgery...

Latest News

New First-Line Treatment for Severe Malaria in U.S.

NewsemiaMarch 31, 2019

by NewsemiaMarch 31, 201900

Title: New First-Line Treatment for Severe Malaria in U.S.Category: Health NewsCreated: 3/28/2019 12:00:00 AMLast Editorial Review: 3/29/2019 12:00:00 AM Source link...

Pediatrics

Anakinra as First-line Monotherapy Wins in sJIA (CME/CE)

NewsemiaMarch 14, 2019

by NewsemiaMarch 14, 201900

(MedPage Today) — Study reports “highly efficacious strategy to induce and sustain inactive disease and to prevent disease- and glucocorticoid-related damage” Source link...

Latest News

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

NewsemiaFebruary 16, 2019

by NewsemiaFebruary 16, 201900

KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/Keytruda?src=hash" target="_blank"gt;#Keytrudalt;/agt;–KEYTRUDA in Combination with Inlyta Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment...

Gastroenterology

No Benefit With Ramucirumab in First-Line Gastric Cancer Tx (CME/CE)

NewsemiaFebruary 8, 2019

by NewsemiaFebruary 8, 201900

(MedPage Today) — Unlike phase II results, no benefit seen in progression-free or overall survival Source link...

Pharma / Biotech

FDA Approves Imbruvica With Gazyva for First-Line CLL Treatment

NewsemiaFebruary 5, 2019

by NewsemiaFebruary 5, 201900

The FDA expanded the labeling for Imbruvicato include use with Gazyva in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Source link...